The U.S. patent office rejected a filing by Alvogen Pine Brook for a review challenging patents on Celgene’s blockbuster myeloma drug Revlimid.
Allergan Plc’s experimental add-on treatment for depression failed three late-stage studies, casting doubts over the company’s drug pipeline and sending the Botox maker’s shares down nearly 4 percent.
Shares of Celgene Corp. dived 8 percent after a major shareholder in Bristol-Myers Squibb Co. came out against a $74 billion merger that would be the pharmaceutical world’s largest-ever takeover.
Mylan NV shares slid 10 percent after the generic drug maker predicted poor 2019 earnings that led some Wall Street analysts to wonder if the company’s finances would worsen further.
French healthcare company Ipsen agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, helping to boost Ipsen’s portfolio of products treating rare diseases.
Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to “step up”, Chief Executive Severin Schwan said.
Orchard Therapeutics announced positive results from a two-year follow up of a stem cell gene therapy for severe combined immune deficiency due to adenosine deaminase deficiency (ADA-SCID).
Shares of Immune Design skyrocketed after Merck announced the acquisition of the Seattle-based oncology company for $300 million in cash.
New Zealand medical device maker Fisher & Paykel Healthcare Corp. Ltd. and U.S. rival ResMed Inc. agreed to settle patent infringement disputes, ending a three-year tussle that spanned the globe and cost each side millions of dollars in legal fees.
Intercept Pharmaceuticals Inc. said the treatment obeticholic acid (OCA) showed an improvement in scarring on the organ in patients with a progressive fatty liver disease.